NCT06926283View on ClinicalTrials.gov

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2030

Conditions
Prostate CancerOther Solid TumorsEwing Sarcoma
Interventions
DRUG

DXC008

Cohort A: Once every 2 weeks (Q2W) with a cycle length of 14 days. Cohort B: Once every 3 weeks (Q3W) with a cycle length of 21 days.

Trial Locations (3)

100034

RECRUITING

Peking University First Hospital, Beijing

100044

RECRUITING

Peking University People's Hospital, Beijing

410000

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hangzhou DAC Biotechnology Co., Ltd.

INDUSTRY